{"entity":{"id":"nct05652868","kind":"trial","name":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1 trial of MYTX-011 run by Mythic Therapeutics, terminated.","summary":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05652868 by Mythic Therapeutics, with 227 participants enrolled, started 2023-03-23. Conditions recorded: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer and Advanced Non-Small Cell Non-Squamous Lung Cancer. Interventions recorded: MYTX-011.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05652868","url":"https://clinicaltrials.gov/study/NCT05652868"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["mytx-011"],"companies":["mythic-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05652868","phase":"1","setting":"A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01","sponsor":"Mythic Therapeutics","enrolled":227,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05652868/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"mytx-011","kind":"drug","name":"MYTX-011","route":"/drugs/mytx-011/"}],"company":[{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/"}]}}